Colorcon Ventures invests in AI provider Atomwise for drug discovery Atomwise

Colorcon Ventures, a $50 million corporate venture fund of Colorcon Inc., has invested in Atomwise, a leading provider of artificial intelligence (AI) solutions for drug discovery and inventor of the first deep learning AI technology for structure-based drug design. The company’s technology, called AtomNet^®, removes the barriers of physical screening that have limited the success of traditional methods for small molecule drug discovery. AtomNet^® currently screens libraries of over 16 billion molecules against novel biological targets in less than two days.

Martti Hedman, CEO at Colorcon, said “Atomwise aligns with the Colorcon Venture fund’s strategic focus on developing transformational technology solutions for the pharmaceutical industry, and Colorcon will be a strong partner for the company. R&D productivity is a major pain point for the pharmaceutical industry. Atomwise is the leading company using AI for small molecule drug discovery, enabling significant time and cost savings for our global customer base. We embrace Atomwise’s approach to partnering with leading pharmaceutical companies in their research & development efforts and are open to strategic alignment with our customers where appropriate.”

Abraham Heifets, Atomwise’s co-founder and CEO, said, “We are pleased to have Colorcon Venture's support as we scale Atomwise. With their support, we will be able to further our mission to make better medicines faster and improve the lives of billions of people.”

For more of the latest science news, straight to your inbox, become a member of SelectScience for free today>>